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ABSTRACT
Hepatocellular carcinoma is the most devastating complication of liver cirrhosis and
diagnosis in earlier stages could be useful in curative interventions. The main aim of
this review was to analyze current diagnostic biomarkers which are available for the
early diagnosis of hepatocellular carcinoma (HCC). For this purpose, we searched
different web databases including Medline/Pubmed. We found multiple significant
serum biomarkers for imperative diagnosis including α- Fetoprotein, Des- γ carboxyprothrombin (DCP), Osteopontin (OPN), Glypican-3 (GPC3), Golgi protein73 (GP73), Squamous cell carcinoma antigen (SCCA), Annexin A2 (ANXA2) and
Heat shock protein 70 (HSP70) but all of these represent low sensitivity and low
specificity. Hepatocellular carcinoma diagnosis have also been reported at the genetic
level with the help of associated genes such as p53, RAS, MERTK (MER-Tyrosine
Kinase), EGF, TGF-β/IGF, ALDH2, CAT, Glutathione S-transferase (GSTM1), X-ray
repair cross-complementing group1 (XRCC1), Receptor tyrosine kinase (ROR1),
RASSF1A, SOCS1, NUF2, CXCL2 and Interleukin-1 Gene (IK-1). Inhibition of these
cancerous genes is under research and could be a novel therapeutic approach in future.
Recently, differential diagnosis with miRNA has been found important for
hepatocellular carcinoma. Anti-miR-122 could revolutionize the early diagnosis of
HCC and has the potential to be marketed for therapy. However, most of the drugs are
under clinical trial phase. It is recommended to use them in conjunction with each
other so these could be employed as a way to decrease mortality and stigma
associated with hepatocellular carcinoma.
Keywords: Hepatocellular carcinoma, diagnosis, genetics, liver cancer, biomarkers.
INTRODUCTION
Cancer refers to a group of diseases involving uncontrolled division of cells
and abnormal cell development which can metastases throughout the body. Cancer is
a major health problem and cause of mortality worldwide. Hepatocellular carcinoma
(HCC) is one of the most devastating types of liver cancer affecting hepatocytes. It is
one of the most prevalent malignancies world-wide. While the death rate due to some
cancers (such as lung cancer) is decreasing with advanced treatments, death rate due
to hepatocellular carcinoma is continuously being increased.
Almost 90 % hepatocellular carcinoma patients also suffer from cirrhosis but
only 3 % cirrhotic patients are affected with hepatocellular carcinoma per year
(Heimbach et al., 2018). People having cirrhosis are more prone of hepatocellular
carcinoma development.

© 2022 by Journal of Bioresource Management is licensed under CC BY 4.0.

24

Kanwal et al., (2022). Biomarkers in Hepatocellular Carcinoma (HCC).
J Biores Manag., 9(3): 24-36.

Large scale hepatocellular carcinoma may be viral due to hepatitis B virus
(HBV) and hepatitis C virus (HCV) or non-viral due to tobacco smoking, aflatoxin
exposure and carcinogens (Baecker et al., 2018). Tobacco smoking, alcohol drugs or
other addictive’s could disrupt our hepatocytes. A well- known aflatoxin produced by
Aspergillus play a drastic role in hepatocellular carcinoma development. Carcinogens
include nitrites, hydrocarbons and organochlorine pesticides may also play a
triggering role for hepatocellular carcinoma development.
Some of the health conditions could also be associated with hepatocellular
carcinoma such as obesity. Obese persons have been found with the highest PAF
values (around 36.4%). Diabetic patients are more prone to hepatocellular carcinoma
as it directly affects liver which is involved in glucose metabolism. The use of oral
contraceptives by females also makes them more prone to hepatocellular carcinoma
development (Lindberg 1992).
During the past decade, a number of advancements have been done in the field
of carcinoma including better medical care, anesthesia, modern surgical techniques
and antineoplastic drugs but the overall survival rate of affected individuals suffering
with hepatocellular carcinoma have remained dismal. Hepatocellular carcinoma is
asymptomatic in the initial stages which makes the diagnosis difficult. It may lead
towards intrusiveness, metastasis and reappearance of tumor (Tang et al., 2004).
With the use of biomarkers, tumors can be detected at an early stage in risk
population and so curative interventions can be made. Moreover, prognostic markers
aid in interrogating the metastatic recurrence of tumor which is useful in treatment
and survival of patients. In developing countries with limited resources, designing and
usage of accessible biomarkers for hepatocellular carcinoma could revolutionize early
diagnosis and treatment of this disastrous illness and can be helpful for people who
would otherwise be on stake. The purpose of this review is to provide a brief account
of the serum, genetic and miRNA associated biomarkers for the early diagnosis of
hepatocellular carcinoma (Figure 1).
α- Fetoprotein (AFP)
α- fetoprotein is glycoprotein belonging to serum albumin family. Gene of this
protein is expressed in liver during fetal development and diminishes after birth. AFP
gene reactivates in pathological conditions like hepatocellular carcinoma. Plasma
concentration 20ng/ml is used as a pathological threshold in humans and 400ng/ml is
considered reliable concentration for hepatocellular carcinoma diagnosis (Nakao and
Ichikawa 2013). According to guidelines of European and American Association for
the Study of Liver Disease, AFP possess low specificity and reduced sensitivity so it
could not be used as diagnostic marker. AFP-L3 % is the most commonly used
glycosylated form of AFP in early diagnosis of tumor when its size is 2cm as its
sensitivity depends on tumor size. AFP shows false negative results in 40 % of
hepatocellular carcinoma patients in early stage and 15-30 % patients possess normal
AFP levels even in advanced stages of cancer which proved it less efficient biomarker
(Cheng et al., 2014).
Des- γ -Carboxyprothrombin (DCP)
DCP is inactive abnormal from of prothrombin and also known as PIVKA-II
(protein induced by vitamin K absence or antagonist-II). It forms as a result of impaired
carboxylation of 10 glutamic acid residues. In 91% hepatocellular carcinoma patients,
DCP is present in their serum suggesting its role as a prognostic marker (Liebman et al.,
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1984). Different studies have described sensitivity and specificity of elevated DCP
concentrations in different stages of hepatocellular carcinoma patients. DCP
concentration vary according to the disease progression and tumor size (Mohammad et al.,
2008). DCP is known to be a favorable biomarker in cases of AFP negative hepatocellular
carcinoma.
Osteopontin (OPN)
OPN is a calcium binding extracellular glycoprotein. This cytokine has
important role in bone mineralization and various abnormal physiological activities
like chronic inflammation therefore it is expressed in malignancies like hepatocellular
carcinoma.
HCC Diagnosis at Protein, Genetic and miRNA level

HCC Detection
miRNA level
Protein level
AFP

Genetic level
P53
Ras

DCP
OPN

MERTK
EGF
TGF-β

GPC3

GP73

ALDH2
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GSTM1
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Figure 1: Biomarkers for Hepatocellular carcinoma (Caldwell et al., 2004).
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OPN has been designated as prognostic marker for progression of
hepatocellular carcinoma (Matsui et al., 2004). OPN overexpression has been found
linked with metastatic potential of HCC. OPN has also been found important in HCV
related hepatocellular carcinoma. AFP shows better diagnostic capability as compared
to OPN but osteopontin possess higher sensitivity in identification of hepatocellular
carcinoma at early stages. A combination of AFP and OPN could be more useful and
reliable (Al-Zoubi et al., 2017).
Glypican-3 (GPC3)
GPC3 is a cell membrane anchoring protein and belongs to heparin sulfate
proteoglycans (HSPGs) family. It shows prominent role in cell growth, differentiation
and cancerous cell proliferation by Wnt and Hedgehog pathways (Scaggiante et al.,
2014). GPC3 has increased expression in hepatocellular carcinoma cells as compared
to normal, unaffected tissues or in the sera of individuals suffering with hepatocellular
carcinoma. Higher expression of GPC3 protein is associated with high tumor and
vascular invasion. It is similar to AFP but reveals low sensitivity and increased
specificity (Xu et al., 2013). Another study reported the increased sensitivity and
higher specificity of GPC3 in the sera of hepatocellular carcinoma patients as
compared to AFP, further suggesting the promising results while using a combination
of both biomarkers (El-Saadany et al., 2018).
Golgi Protein-73 (GP73)
GP73 also referred as Golgi phosphoprotein 2, is transmembrane glycoprotein
consisting of 73 kDa. It is found overexpressed in fibrosis, carcinogenesis and
hepatocellular carcinoma patients as compared to normal controls. GP73 is reported
as diagnostic marker of hepatocellular carcinoma due to its elevated expression in
affected individuals. After surgical hepatectomy, the diagnostic capability of GP73 is
far greater than AFP and is a beneficial biomarker for the follow-up of hepatocellular
carcinoma patients. Limitations include serum GP73 increase only in hepatocellular
carcinoma patients having cirrhosis, but not in patients without cirrhosis making it an
unsuitable hepatocellular carcinoma diagnosis biomarker (Liu et al., 2017). Serum
GP73 can be used as a potent biomarker in predicting liver inflammation in chronic
HBV patients. A recent study has reported the use of both serum and mRNA of GP73
as diagnostic marker for early detection of hepatocellular carcinoma (Farag et al.,
2019). To solve the controversy of GP73 as biomarker, a meta-analysis has shown
its predictive role for hepatocellular carcinoma invasion and metastasis (Zhang et al.,
2019).
Squamous Cell Carcinoma Antigen (SCCA)
SCCA is a high molecular weight serine protease inhibitor which play
important role in epithelial cancers. Its two isoforms SCCA1 and SCCA2 are at higher
level in hepatocellular carcinoma patients as compared to normal ones. The third
genetic isotype of SCCA characterized by G351A polymorphism has been found in
some cases of hepatocellular carcinoma. Due to its presence in hepatocellular
carcinoma, it is documented as possible diagnostic biomarker (Soyemi et al., 2012).
Important role of SCCA in diagnosis of hepatocellular carcinoma has been found with
sensitivity of 77.6% and specificity of 84.4%. This biomarker does not have the fair
diagnostic value for hepatocellular carcinoma making it not the perfect one instead of
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other biomarkers like AFP, GP73 etc. SCCA possess higher sensitivity while AFP has
higher specificity, so a combination of the two biomarkers make a good predicting
test with better sensitivity for hepatocellular carcinoma (Abdelhamid et al., 2020).
Annexin A2 (ANXA2)
ANXA2 is a 36 kDa cytoskeletal protein which binds with calcium, present at
the surface of the endothelial cells and on different kinds of cancerous cells. ANXA2
plays significant role in regulatory activities like cell invasion, migration, adhesion
and proliferation. It has been reported in different types of cancers as in breast, liver,
ovary and hepatocellular cancer (Lokman et al., 2011, Mohammad et al., 2008). As
compared to AFP, ANXA2 has been utilized as a serological biomarker for the early
diagnosis of hepatocellular carcinoma with advanced sensitivity and acute specificity.
Serum ANXA2 has been used as diagnostic marker with sensitivity of 74% and
specificity of 88% (Shaker et al., 2017). Elevated expression of ANXA2 in both AFP
positive and AFP negative patients complements that this combination could form a
better diagnostic marker (El-Gezawy et al., 2018).
Heat Shock Protein 70 (HSP70)
HSPs are cellular molecules belonging to protein family that are expressed
under the effect of stressors such as hypoxia, nutrient deficiency, starvation and
carcinogenesis. Among HSPs, the most common is a molecular chaperon Heat shock
protein 70 (HSP70) whose level is increased as a result of cell survival protection,
heat and other stressors. The level of HSP70 is regulated by heat shock factor-1 (HSF1). HSF-1 can block apoptosis at different levels and its role in cancer is might be due
to its anti-apoptotic activity. HSP70 and HSF-1 are found to be involved in
hepatocellular carcinoma metastasis. Affected individuals suffering from
hepatocellular carcinoma and liver cirrhosis, serum levels of HSP70 are generally
greater as compared to normal individuals (Gehrmann et al., 2014). HSP70 expression
is upregulated during early stages of hepatocellular carcinoma and so it is used as
potential sensitive biomarker. HSP70 in combination with other markers like
glutamine synthetase could form putative diagnostic biomarker for hepatocellular
carcinoma (Jiang et al., 2020). GPC3 and HSP70 appear to be useful as individual
markers for hepatocellular carcinoma arising in non-cirrhotic livers (Uthamalingam et
al., 2018).
HCC Diagnosis at Genetic Level
Mutation in driver genes and pathways convert normal cells into tumorous and
allow them to proliferate without constraints (Zhang et al., 2018). Hepatotoxic stress,
viral infections or carcinogens can proliferate mutations in tumor-suppressor genes
(Tannapfel and Wittekind 2002). Changes in the promoter region, gene amplification
or point mutations may result disrupting cell cycle leading towards development of
metastatic cancer. Thus, inhibition of cancerous genes from outside sources could be a
novel therapeutic approach for the treatment of various types of cancer (Kanda et al.,
2015).
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p53
p53 mutations have been found in 30 % of hepatocellular carcinoma cases
worldwide out of which most mutations are somatic. A hotspot mutation for
hepatocellular carcinoma is p.Arg249Ser (guanine-to-thymine transversion) (Qin et
al., 2020). Occurrence of this “hotspot” mutation is extremely low in hepatocellular
carcinoma patients who are from Australia, Japan, United States, or Europe. Among
664 hepatocellular carcinoma patients, only three mutations (two in Japan and one in
Europe) have been recognized which revealed that other genes might be intricate in
the process of hepatocellular carcinoma development (Tannapfel and Wittekind
2002).
RAS Gene
Three human Ras genes (K-RAS, N-RAS and H-RAS) encodes small K-Ras4A,
K-Ras4, N-Ras and H-Ras guanosine triphosphate (GTP) binding proteins which
regulate the growth of cells, apoptosis and cellular differentiation. Single amino acid
substitutions at K-ras codon 61, H-ras codon 13 or N-ras codon 12 consequences in
the development of mutant Ras proteins which are insensitive to GAP (Clark et al.,
1993). As a result, mutant oncogenic Ras proteins remain active and bound to GTP.
Overexpression of Ras has been demonstrated in hepatocellular carcinoma. Likewise,
inhibitors of Ras pathway are downregulated in HCC. K-Ras codon 12, H-Ras codon
12 and N-Ras codon 6 are the most prevalent mutations of Ras proteins. So these
mutations in RAS genes can be used as biomarker tool in cancer diagnosis (Chen et
al., 2020).
MERTK (MER-Tyrosine Kinase)
MERTK resides on chromosome 2 and plays important role in controlling
tumor associated macrophages (TMA). MERTK, rs6726639 causes progression of
hepatocellular carcinoma in patients. These patients have achieved sustained virologic
response (SVR) which can be treated with antiviral substances. The AA allele of
rs6726639 MERTK is considered to be responsible for higher risk of developing
hepatocellular carcinoma in patients with cirrhosis after HCV eradication by DAAs.
This discovery can be useful in hepatocellular carcinoma early diagnosis by
considering this mutation an important biomarker of hepatocellular carcinoma (Di
Marco et al., 2019).
EGF
SNP rs4444903 of EGF, also known as +61, regulates the production of EFG.
This polymorphism is present in the promoter region of epidermal growth factor EGF.
The rs4444903 (G) allele has been found to be responsible for increasing EGF levels
than the (A) allele. Significant association of this polymorphism with hepatocellular
carcinoma development has been found so it can be used as a biomarker if more
research is carried out on this perspective (Suenaga et al., 2013).
TGF-β/IGF
Transforming growth factor (TGF) β plays a significant role in apoptosis,
growth rate and cell cycle. In 10% of hepatocellular carcinoma cases, mutations in
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SMAD2 and SMAD4 cause genetic changes of TGF-β pathway. Mutation in TGF-β
receptor (TGF-β1RII) gene causes hepatocellular carcinoma development by
inhibiting TGF-β signaling. Insulin-like growth factor 2 receptor/ Mannose-6phosphate (IGF2R/M6P) activates TGF-β. In about 30% hepatocellular carcinoma
patients, M6P/IGF2R mutation plays significant role in hepatocellular carcinoma
development. Different genes of TGF-β/IGF pathway may be mutated in
hepatocellular carcinoma which hampers its use for diagnosis (Tannapfel and
Wittekind 2002).
ALDH2
Mitochondrial aldehyde dehydrogenase enzyme is encoded by ALDH2 gene.
Significant association has been found between ALDH2 and hepatocellular carcinoma
development but there is ultimate need to further investigate these associations (Kato
et al., 2003).
CAT
CAT gene encodes antioxidant enzyme catalase. Polymorphism of this gene SNP
rs1001179.C>T has been found to be associated with hepatocellular carcinoma
development but it needs further investigation (Ezzikouri et al., 2010, Nahon et al.,
2012).
Glutathione S-transferase (GSTM1)
GSTM1 encodes Glutathione S-transferase enzyme belonging to Mu class of
enzymes. These enzymes play a significant role in detoxification of electrophiles and
in carcinogenesis. GSTM1 is present in a gene cluster on chromosome 1p13.3 and is
found to be highly polymorphic. A deletion of this gene has been found to be
associated with hepatocellular carcinoma (Asim et al., 2010, El-Moneim et al., 2008).
X-ray Repair Cross-Complementing Group1 (XRCC1)
XRCC1 plays essential role in hepatocellular carcinoma development. The
most devastating mutations causative for hepatocellular carcinoma development have
been found among chronic hepatitis C patients c.1254C>T (rs2293035) and
c.1517G>C (rs139599857) in XRCC1 (Arafa et al., 2019). Further research is needed
for using this polymorphism as biomarker for hepatocellular carcinoma diagnosis.
Receptor Tyrosine Kinase (ROR1)
Receptor tyrosine kinase (ROR1) has functional contribution in
hepatocarcinogenesis. In human and mouse hepatocellular carcinoma cell lines,
ROR1 antibodies are utilized for the localization of ROR1 protein. Knockdown of
ROR1 declines proliferation and enhances apoptosis. Hence it shows ROR1 can have
diagnostic value in hepatocellular carcinoma and can be proved as an important
biomarker (Cetin et al., 2019).
RASSF1A and SOCS1
DNA methylation is considered as most significant genetic modification in
human cancers. Instead of performing biopsy, methylation identification can be a
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significant prognostic biomarker for hepatocellular carcinoma (HCC). In 38% and
40% of affected individuals suffering with hepatocellular carcinoma, methylation
patterns of SOCS-1 and RASSF1A respectively, have been found causative. So SOCS1 and RASSF1A methylation status may be used a biomarker tool for hepatocellular
carcinoma (Pasha et al., 2019).
NUF2
Early tumor recurrence after getting treated is major challenge in
hepatocellular carcinoma so NUF2 that encodes kinetochore protein is considered an
important biomarker for diagnosis of early recurrence of hepatocellular carcinoma. In
a study in which whole genome expression microarrays have been performed on 64
primary hepatocellular carcinoma tumors, NUF2 has been found considerably related
with early recurrent hepatocellular carcinoma tumors (Wang et al., 2019).
CXCL2
Epigenetics causes shushing of tumor suppressor genes by methylation of
promoter CpG islands. After treatment with DNA demethylating agent, 5-aza-2′deoxycytidine, the CXCL2 expression and methylation has been found significantly
down regulated in hepatocellular carcinoma tissues. Hence CXCL2, may be used as an
important biomarker for diagnosis and treatment of hepatocellular carcinoma (Subat
et al., 2019).
Interleukin-1 Gene (IK-1)
Interleukin family is a group of cytokines that regulate immune and
inflammatory responses. In 274 Japanese HCV patients, IK-1 polymorphism has been
studied along with its association with occurrence of hepatocellular carcinoma by
applying standard PCR-based genotyping techniques. IL-1-511/-31 haplotype C-T
and IL-1-31 genotype T/T has been found significantly associated with hepatocellular
carcinoma occurrence (Wang et al., 2003).
Hepatocellular Carcinoma Diagnosis at Micro-RNA level
Human genome encodes more than one thousand types of micro-RNA
(miRNA) involved in the process of gene silencing. miRNA pair up with its target
messenger RNA (mRNA) molecules due to complementary sequence within the target
mRNA. This pairing induces degradation of mRNA either by its cleavage or by
chopping off its poly-A tail and results in decreased expression of a target gene or
mRNA into protein (Xu et al., 2013).
miRNAs are being recognized as potential biomarkers in diagnostic studies as
they are quite stable and can be detected in clinical samples such as bodily fluids,
urine, serum, blood and cerebrospinal fluid. Different disease conditions, particularly
cancer, leads to deviation from normal expression of various miRNAs making them a
significant biomarker in diagnosis of hepatocellular carcinoma. miRNA are also
referred as oncomirs due to their association with many cancers as abnormal
expression of miRNA may serve in early diagnosis of cancers (Su et al., 2019).
Expression of characteristic miRNAs has been found as a promising tool in
prediction, diagnosis, and prognosis of therapeutic responses in hepatocellular
carcinoma. As the hepatocellular carcinoma progresses, unique pattern of miRNAs
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Upregulation

expression vary gradually and many tumor suppressing genes are recognized as their
potential target sites. Differential miRNA expression in hepatocellular carcinoma is
studied extensively and demonstrated comprehensively, enabling them to diagnose
hepatocellular carcinoma at early stages from samples including blood, body fluids
and tissue specimens. Comparison of various miRNAs in normal healthy liver tissues
and tissue specimen from cancerous liver has demonstrated miR-122 as the most
abundant miRNA found in healthy liver tissues whose level is downregulated during
the progression of hepatocellular carcinoma (Liang et al., 2020).
Another miRNA that express in normal liver tissue is miR-199a/b whose level
has been found downregulated during hepatocellular carcinoma development leading
to poor survival rate (Lou et al., 2020).
Variation in expression of miRNAs in serum can also be detected. Level of
miR-122 in the serum of patients suffering from hepatocellular carcinoma has been
found upregulated. Chemotherapy in these patients causes drop in serum expression
of miR-122 and hence serve as potent biomarker for hepatocellular carcinoma
severity during its treatment (Lou et al., 2020). A combination of three miRNAs: let7f, miR-375 and miR-25 discriminate serum sample of hepatocellular carcinoma from
healthy controls. Deviation in serum level of seven miRNAs , miR-505, miR-192,
miR-145, miR-143, miR-29a, miR-29c, and miR-133a can detect hepatocellular
carcinoma with much better sensitivity as compared to other biomarkers (Fu et al.,
2019).
Decreased expression of miR-150 in the serum of HBV-related hepatocellular
carcinoma patients has indicated considerable low survival rate. Hepatocellular
carcinoma and chronic hepatitis can also be differentiated through the change in
profile of circulating miR-199a, miR-16 and miR-195 (Sui et al., 2019). However, a
reduced serum level of some miRNAs such as miRNA-21, miRNA-122 and miRNA223 is involved in Hepatitis as well as hepatocellular carcinoma.
It is very obvious from above mentioned findings to establish the role of circulating
miRNAs as potential diagnostic marker in hepatocellular carcinoma. Figure 2
demonstrates distinctive upregulation or downregulation of various circulating
miRNAs in hepatocellular carcinoma patients.

miR-122,
miR-125,
miR-130a,
miR-150,
miR-199,
miR-200

Downreulation

miR-18,
miR-21,
miR34a,
miR-221,
miR-222,
miR-224,
miR-301,
miR-373

Figure 2: Summary of some circulating miRNAs.
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miRNA that are upregulated are shown on left side and miRNAs that are downregulated are indicated
on right side.

Apart from diagnosis, miRNAs have tremendous potential to be used as
prognostic markers. They may help in determination of tumor size, metastasis stage of
hepatocellular carcinoma, recurrence and even the survival rate of patient.
Downregulation of miR-100 and miR-22 along with the upregulation of miR-221
depicts the distant metastasis in primary hepatocellular carcinoma tissues (Fu et al.,
2019). Advancement of tumor can be correlated with the change in expression of
miR-222 in the serum (Eguchi et al., 2018). A higher expression of miR-182, miR155, miR-372 and miR-25 in hepatocellular carcinoma tissues portrays lesser survival
rate. However, the decreased expression level of miR-29a-5p, miR-100, miR-29,
miR-101 and miR-148 is indicative hepatocellular carcinoma treatment leading to
increased survival chances (Cetin et al., 2019).
CONCLUSION
This study concludes that different biomarkers could be employed due to their
differential expression. Serum, genetic or miRNA associated biomarkers have the
remarkable potential for the early diagnosis of hepatocellular carcinoma (HCC) but
these could be used in conjunction with each other.
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